Valion Bio (NASDAQ: VBIO) has outlined the perspectives of its new board chair, Thomas H. Jensen, on advancing Entolimod—an investigational Toll-like receptor 5 (TLR5) agonist being developed as a potential medical...
Closely held Wandercraft has announced the acquisition of Ekso Bionics from a subsidiary of ChronoScale Holdings Corporation (NASDAQ: CHRN), uniting two leaders in robotic mobility to form the world’s leading medical...
Perimeter Medical Imaging AI (TSX-V: PINK; OTCQX: PYNKF) has announced that Michelle Caron, CPA, has been appointed to its board of directors (BOD), effective immediately. In a finance career spanning more than 28...
AI/ML Innovations (CSE: AIML; OTCQB: AIMLF; FWB: 42FB) has appointed Lynn Chapman, CPA, CA, as chief financial officer (CFO), effective October 1, 2026. Mr. Chapman brings more than 15 years of financial and managerial...
Surrozen (NASDAQ: SRZN) has announced its Investigational New Drug (IND) application for SZN-8141 for the treatment of diabetic macular edema (DME) has become effective, enabling advancement to clinical development. SZN...
Tenon Medical (NASDAQ: TNON) has announced the full commercial launch of its new titanium 3D-printed lateral screw as part of the SImmetry+ SI Joint Fusion System following the successful completion of the...
Connect Biopharma (NASDAQ: CNTB) has announced topline results from its global Phase 2 study evaluating rademikibart, its next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody as...
Valion Bio (NASDAQ: VBIO) and closely held Shear Kershman Laboratories (SKL) announced the successful completion of formulation work under the companies’ ongoing program to develop a novel oral mucosal formulation of...
Immix Biopharma (NASDAQ: IMMX) has reported interim data showing an 89% complete response (CR) rate across all 45 enrolled patients, based on an assessment by an independent review committee, from its NEXICART-2 Phase 2...
Nexalin Technology (NASDAQ: NXL) has announced the appointment of Robert DiTota as senior strategic advisor, global commercialization, effective September 15, 2026. Mr. DiTota brings more than 20 years of neuroscience...
Clear Street initiated coverage of Q32 Bio (NASDAQ: QTTB) with a “buy” rating and price target of $38.00. The stock closed at $8.77 on September 25. Q32 Bio is a clinical-stage biotechnology company developing therapies...
Lucid Capital Markets initiated coverage of Lensar (NASDAQ: LNSR) with a “buy” rating and price target of $11.00. The stock closed at $6.92 on September 25. Lensar designs, manufactures, and commercializes femtosecond...